Inactive Instrument

Press Releases AIT Therapeutics Inc Other OTC

Equities

US50027L1070

End-of-day quote Other OTC Other stock markets
- ^USD	-

Apr. 30	Truist Lowers Price Target on Beyond Air to $8 From $10, Keeps Buy Rating	MT
Feb. 12	Beyond Air, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Beyond Cancer Selected to Present on the Clinical Development of Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2024 American Society of Clinical Oncology Annual Meeting	May. 01	AQ
Beyond Air® Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrants	Mar. 20	AQ
Beyond Air : Corporate Presentation	Mar. 13	PU
Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2024	Feb. 12	AQ
Beyond Air® Schedules Third Fiscal Quarter 2024 Financial Results Conference Call and Webcast	Jan. 18	AQ
Beyond Cancer™ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumors	Dec. 27	AQ
Thinking about buying stock in Polished.Com, Mereo BioPharma, Fusion Pharmaceuticals, Luminar Technologies, or Beyond Air?	Dec. 20	PR
Beyond Air® To Participate in the 35th Annual Piper Sandler Healthcare Conference	Nov. 15	AQ
Thinking about buying stock in Invo Bioscience, Singing Machine Company, Beauty Health, Beyond Air, or Tivic Health Systems?	Nov. 14	PR
Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2024	Nov. 13	AQ
Beyond Cancer™ Presents Positive First-in-Human Clinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting	Nov. 03	AQ
Beyond Air : Corporate Presentation	23-10-30	PU
Beyond Air® Schedules Second Fiscal Quarter 2024 Financial Results Conference Call and Webcast	23-10-19	AQ
Beyond Air® To Participate in the Truist Securities BioPharma Symposium	23-10-17	AQ
Beyond Cancer™ Publishes Pre-Clinical Data in Cells Demonstrating that the Combination of Ultra-High Concentration Nitric Oxide (UNO) and Anti-mPD-1 Therapy Improves Tumor Regression Rates and Survival in Mice	23-10-17	AQ
Beyond Cancer™ Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) in Combination with Checkpoint Inhibitor Therapy During the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics	23-10-16	AQ
Beyond Air® Receives Innovative Technology Contract from Vizient for LungFit®PH	23-10-16	AQ
Beyond Cancer™ Selected to Present Proffered Posters Discussing Data from the UNO Therapy Program at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics	23-10-04	AQ
Beyond Air® To Participate in the Roth MKM 2023 Healthcare Opportunities Conference	23-10-02	AQ
Beyond Cancer™ to Present Initial Clinical Data for Ultra-High Concentration Nitric Oxide Therapy at the 2023 SITC Annual Meeting	23-09-27	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases AIT Therapeutics Inc Other OTC

Equities

US50027L1070

Press Releases

Filters